Novo Nordisk’s CagriSema Shows Strong Weight-Loss Results But Trails Eli Lilly’s Tirzepatide in Latest Clinical Data

A New Chapter in the Global Anti-Obesity Drug Race

 

The competition to develop next-generation obesity therapies intensified following the release of new Phase III clinical data for CagriSema, an investigational drug from Novo Nordisk.

According to results from the REDEFINE-4 trial, patients treated with CagriSema achieved an average weight reduction of approximately 23% after 84 weeks, a significant outcome in the field of obesity medicine. However, the result fell short of the roughly 25.5% weight loss reported for tirzepatide, a leading therapy developed by Eli Lilly.

 

Distinct Therapeutic Strategies

CagriSema combines two long-acting agents:

Cagrilintide, an amylin receptor agonist

Semaglutide, a GLP-1 receptor agonist

This fixed-dose, once-weekly injectable therapy is designed to enhance satiety and reduce caloric intake.

In contrast, tirzepatide operates through a different biological mechanism. It is a dual incretin therapy that activates both GLP-1 and GIP receptors, pathways known to regulate glucose metabolism, appetite, and energy balance.

Researchers note that while both drugs significantly reduce body weight, their underlying mechanisms differ in scope. CagriSema primarily enhances feelings of fullness and decreases food consumption, whereas tirzepatide may exert broader metabolic effects, including improved insulin sensitivity and modulation of fat tissue.

 

Regulatory Progress and Commercial Stakes

Novo Nordisk submitted CagriSema to the U.S. Food and Drug Administration in December 2025 for chronic weight management. If approved, the drug could expand the company's portfolio beyond its blockbuster GLP-1 therapy semaglutide.

Semaglutide products generated approximately $36.1 billion in revenue in 2025, underscoring the enormous commercial potential of obesity and diabetes treatments.

Meanwhile, tirzepatide has rapidly emerged as a major competitor. Sales of the therapy reached about $36.5 billion in 2025, surpassing semaglutide and positioning it as one of the world's top-selling pharmaceuticals.

 

Evidence of Superior Efficacy

Earlier comparative studies conducted by Novo Nordisk showed that CagriSema produced greater reductions in both body weight and HbA1c levels than semaglutide alone at 68 weeks across all tested doses.

However, the latest REDEFINE-4 results suggest that tirzepatide still holds a modest efficacy advantage in overall weight reduction.

Experts attribute this difference to tirzepatide's dual-receptor mechanism, which influences not only appetite but also metabolic processes such as glucose regulation and fat utilization.

 

Implications for Future Obesity Therapies

The new data highlight a broader shift in obesity treatment toward multi-target pharmacology. Rather than relying solely on appetite suppression, emerging therapies aim to address the complex hormonal systems governing energy balance and metabolism.

Despite the competitive landscape, analysts emphasize that both drugs represent transformative advances. Weight reductions exceeding 20% approach outcomes historically achievable only through bariatric surgery.